Executive Director, U.S. HCP Marketing
Madrigal Pharmaceuticals Inc - 2 Locations
Posted Oct 27, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Offered From the posting source checked Nov 17, 2026
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified checked Nov 20, 2026
- Salary
- $290K-$354K From the posting source checked Nov 17, 2026
- 401(k) match
- Reported from DOL Form 5500 industry filing (not employer-specific)
Was this benefit information wrong? Tell us.
Market context
- U.S. role benchmark (BLS OEWS)
- $93,011 U.S. median for this role
- Projected growth (BLS Employment Projections)
- +5.1% - Faster than average
U.S. benchmark only; posted salary is not compared across countries or currencies.
Matched to SOC 13-1161 - Marketing aggregate by role bucket.
Source:U.S. Bureau of Labor Statistics, OEWS, May 2024andEmployment Projections, 2024-2034.
Role
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Company
- Equity
- Offered Verified - SEC 10-K source checked Nov 17, 2026
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Executive Director, U.S. HCP Marketing 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. We are seeking an Executive Director, U.S. HCP Marketing for Rezdiffra, to shape and actualize the HCP marketing strategy for Rezdiffra and the broader MASH therapeutic category. This role is a high-visibility role for a leader who can operate can shape brand and content strategy while being comfortable with a roll your sleeves up approach in tactical development and execution. This individual will need to embrace a business-owner mentality needed to be successful at a rapidly growing company fueled
Read the full description at madrigalpharma.wd501.myworkdayjobs.com. FewerJobs shows a preview and links to the original posting.
Apply link verified; last checked Nov 20, 2026.
What verified means
Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.
Related jobs
Director, Field Execution and Excellence
Madrigal Pharmaceuticals Inc - Remote - US
Senior Director, U.S. HCP Marketing
Travere Therapeutics Inc - 2 Locations
Associate Director U.S. Marketing, Crohn’s Disease HCP Strategy
Merck & Co., Inc. - USA - Pennsylvania - North Wales (Upper Gwynedd)
Director, HCP Marketing
Bicara Therapeutics Inc - Boston, MA, United States